Dolutegravir plus lamivudine maintains human immunodeficiency virus-1 suppression through week 48 in a pilot randomized trial
Clinical Infectious Diseases May 28, 2018
Taiwo BO, et al. - Researchers performed a randomized pilot clinical trial demonstrating dolutegravir plus lamivudine as noninferior to continuation of standard 3-drug maintenance antiretroviral therapy. In the participant who experienced virologic failure while receiving dolutegravir plus lamivudine, drug resistance did not emerge.
Go to Original
Only Doctors with an M3 India account can read this article. Sign up for free or login with your existing account.
4 reasons why Doctors love M3 India
-
Exclusive Write-ups & Webinars by KOLs
-
Daily Quiz by specialty
-
Paid Market Research Surveys
-
Case discussions, News & Journals' summaries